Side-by-side · Research reference
GHRP-6vsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED10/36 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
GHRP-6
P21
Primary target
Ghrelin receptor (GHS-R1a)Bowers 1990
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Feedback intact?
—
—
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
P21
Frequency
1–3× per day
—
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 1 + clinical practiceBowers 1990
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Duration
8–12 weeks on / 4 off
Not specified
Reconstitution
Bacteriostatic water
—
Timing
Pre-meal preferred for appetite support
—
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
Route
—
Presumed subcutaneous or intraperitoneal (animal studies)
04Side Effects & Safety
Parameter
GHRP-6
P21
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Human safety data
—
None available
No clinical trials in humans.
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
P21
- ·Use in humans not validated
Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
GHRP-6
P21
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Not established. No FDA approval, no clinical trial data.
2. Injection site
SQ — abdomen. Rotate sites.
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
—
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
—
5. Needle
29–31G, 4–8 mm insulin syringe.
—